Glucagon-like peptide 1 agonists and the development and growth of pancreatic β-cells
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) is an intestine-derived insulinotropic hormone that stimulates glucose-dependent insulin production and secretion from pancreatic β-cells. Other recognized actions of GLP-1 are to suppress glucagon secretion and hepatic glucose output, delay gastric emptying, reduce food intake, and promote glucose disposal in peripheral tissues. All of these actions are potentially beneficial for the treatment of type 2 diabetes mellitus. Several GLP-1 agonists are in clinical trials for the treatment of diabetes. More recently, GLP-1 agonists have been shown to stimulate the growth and differentiation of pancreatic β-cells, as well as to exert cytoprotective, antiapoptotic effects on β-cells. Recent evidence indicates that GLP-1 agonists act on receptors on pancreas-derived stem/progenitor cells to prompt their differentiation into β-cells. These new findings suggest an approach to create β-cells in vitro by expanding stem/progenitor cells and then to convert them into β-cells by treatment with GLP-1. Thus GLP-1 may be a means by which to create β-cells ex vivo for transplantation into patients with insulinopenic type 1 diabetes and severe forms of type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Farilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664 · cited 3×
“Human islets treated with GLP-1 have a downregulation of caspase 3 both at the level of messenger RNA and at the level of active protein and an upregulation of the antiapoptotic protein Bcl-2 (21).”
BackgroundGlucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589
Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats
Farilla, L., Hui, H., Bertolotto, C., Kang, E., Bulotta, A., Di Mario, U., & Perfetti, R. (2002) · Endocrinology · doi:10.1210/en.2002-220405 · Cited by 502 · cited 4×
“In the ZDF rat model, GLP-1 stimulates increased replication of insulin-negative cells both within islets and in the exocrine pancreatic parenchyma (22).”
BackgroundInfluentialButeau, J., Roduit, R., Susini, S., & Prentki, M. (1999) · Diabetologia · doi:10.1007/s001250051238 · Cited by 413 · cited 7×
“In this system, GLP-1 also activates PI3K (10) and atypical PKC- (9), supporting a model with a cascade of signaling in which activation of the GLP-1 receptor leads (via c-src) to the autocrine or paracrine release of betacellulin, activation of the EGFR, and activation of PI3K and PKC- (8) (Fig.”
BackgroundInfluentialLu, M., Wheeler, M. B., Leng, X. H., & Boyd, A. E. (1993) · Endocrinology · doi:10.1210/endo.132.1.8380389 · Cited by 151
Cited by
Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery.
Service, G. J., Thompson, G. B., Service, F. J., Andrews, J. C., Collazo-Clavell, M. L., & Lloyd, R. V. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043690 · Cited by 779
Liu, Z., & Habener, J. F. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706105200 · Cited by 326
Self-citationAdult diffuse nesidioblastosis: genetically or environmentally induced?
Klöppel, G., Anlauf, M., Raffel, A., Perren, A., & Knoefel, W. T. (2008) · Human Pathology · doi:10.1016/j.humpath.2007.09.010 · Cited by 108
Motté, E., Szepessy, E., Suenens, K., Stangé, G., Bomans, M., Jacobs-Tulleneers-Thevissen, D., Ling, Z., Kroon, E., Pipeleers, D., & Beta Cell Therapy Consortium EU-FP7 (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00219.2014 · Cited by 100
Vidal, J., Nicolau, J., Romero, F., Casamitjana, R., Momblan, D., Conget, I., Morínigo, R., & Lacy, A. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1620 · Cited by 94
Metadata
- Authors
- List, J. F., & Habener, J. F.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2004-06
- Volume
- 286
- Issue
- 6
- Pages
- E875-E881
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W2128418690
- Cited by
- 94
- References
- 7
- FWCI
- 8.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon-like peptide 1 agonists and the development and growth of pancreatic β-cells. https://app.cochat.ai/papers/10.1152/ajpendo.00007.2004
- The paper
- List, J. F., & Habener, J. F. (2004). Glucagon-like peptide 1 agonists and the development and growth of pancreatic β-cells. American Journal of Physiology-Endocrinology and Metabolism. https://doi.org/10.1152/ajpendo.00007.2004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.